55 results
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
of a simple majority of the valid votes cast.
No effect
Not Applicable (1)
Affirmative vote of a simple majority of the valid votes cast.
No effect …
Affirmative vote of a simple majority of the valid votes cast.
No effect
Not Applicable (1)
Affirmative vote of a simple majority of the valid votes cast
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
combination with ezetimibe in the majority of European countries, if approved. Subject to receipt of marketing approval, our current plan … prepared by the Board of Directors which can only be overruled by a two-thirds majority of votes cast representing more than half of our issued share
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
majority of the valid votes cast.
No effect
Not Applicable (1)
Affirmative vote of a simple majority of the valid votes cast.
No effect
Affirmative … vote of a simple majority of the valid votes cast.
No effect
Not Applicable (1)
Affirmative vote of a simple majority of the valid votes cast.
No effect
POS AM
NAMS
NewAmsterdam Pharma Company NV
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
or that is represented at a General Meeting.
Decisions of the General Meeting are taken by a simple majority of votes cast, except where Dutch law … or the Articles of Association provide for a qualified majority or unanimity. Subject to any provision of mandatory
Dutch law and any higher quorum requirement
424B3
NAMS
NewAmsterdam Pharma Company NV
12 Mar 24
Prospectus supplement
4:18pm
of the share capital that is provided or that is represented at a General Meeting.
Decisions of the General Meeting are taken by a simple majority … of votes cast, except where Dutch law or the Articles of Association provide for a qualified majority or unanimity. Subject to any provision of mandatory
POS AM
hrqw76ox 46
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
8-K
EX-99.1
86jak8z0lw0rhq7o
28 Feb 24
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
8:11am
10-K
p0gfecr4y kpygse6
28 Feb 24
Annual report
8:00am
10-K
EX-97.1
0k2o6h28bin0smgwr
28 Feb 24
Annual report
8:00am
10-K
EX-4.4
n5qpox dnuvwbvfyq
28 Feb 24
Annual report
8:00am
10-K
EX-10.4
lrgqwixtw4b 0n4o
28 Feb 24
Annual report
8:00am
424B5
0bj2yvd 7qdw3
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
bs49quty1kegty2w9qv
13 Feb 24
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
j9m2 35vghs
22 Jan 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
e6k8rjob5r8iqx6fim8f
8 Jan 24
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
8:21am
424B3
tnqvgi i9
19 Dec 23
Prospectus supplement
4:36pm
F-3
EX-4.1
q2z1aidi0 f3f9jt0pi
7 Dec 23
Shelf registration (foreign)
4:16pm
F-3
EX-4.2
ajqv0 qi1
7 Dec 23
Shelf registration (foreign)
4:16pm
F-3
y9ojas
7 Dec 23
Shelf registration (foreign)
4:16pm
424B3
2tchvq
15 Aug 23
Prospectus supplement
4:52pm